Candel Therapeutics, Inc.

What they do

Candel develops engineered viruses designed to induce immunogenic cell death in the tumor microenvironment, releasing tumor neo-antigens and creating a pro-inflammatory state intended to drive systemic anti-tumor immunity against injected and uninjected tumors. The company has two clinical platforms: genetically modified adenovirus and herpes simplex virus constructs. Its lead candidate, aglatimagene besadenovec (formerly CAN-2409), is an adenovirus administered with the prodrug valacyclovir and is in a pivotal phase 3 trial in localized prostate cancer, with a phase 3 trial (AURORA) also started in stage IV non-squamous NSCLC. A second candidate, linoserpaturev, is being planned for a randomized phase 2 dose-regimen-finding trial in recurrent glioblastoma.

Revenue drivers

• Aglatimagene besadenovec (prostate cancer) — Lead adenovirus product candidate in a pivotal phase 3 trial in localized, intermediate- to high-risk prostate cancer; not yet approved or marketed, so it generates no product revenue today.
• Aglatimagene besadenovec (NSCLC) — Same candidate being evaluated in the global pivotal phase 3 AURORA trial in stage IV non-squamous NSCLC with progressive disease despite pembrolizumab; no revenue to date.
• Linoserpaturev (HSV platform) — HSV-based candidate advancing toward a potential randomized phase 2 dose-regimen-finding trial in recurrent glioblastoma; no revenue.
• Reported revenue — Annual revenue was $125,000 in each of 2020, 2021 and 2022, with quarterly revenue of $31,000-$32,000 in 2022, indicating no meaningful commercial revenue base.

Recent performance

Candel reported a net loss of $38.2M for full-year 2025, with diluted EPS of -$0.72, compared with a $55.2M net loss and -$1.74 EPS in 2024. Operating cash flow was -$38.3M in 2025 versus -$27.0M in 2024. As of June 30, 2026, the company reported total assets of $208.1M, total liabilities of $82.0M, shareholders' equity of $126.1M, and cash and cash equivalents of $201.6M. The company reported no meaningful quarterly revenue in 2022 and lists no commercial-stage product revenue in recent disclosures.

Strategy

The company is preparing a Biologics License Application for aglatimagene in localized, intermediate- to high-risk prostate cancer, targeted for the fourth quarter of 2026, supported by pre-BLA readiness work including CMC activities, clinical study reports and BLA modules. A process validation campaign for drug substance and drug product is being run at its contract development and manufacturing organization, and new clinical material has been produced for the NSCLC phase 3 trial. Candel appointed Mark Sims as Chief Commercial Officer to support a potential U.S. commercial launch of aglatimagene in localized prostate cancer in 2027, if approved. It is also advancing development planning for linoserpaturev in recurrent glioblastoma.

Risks

• No approved product or product revenue — The company generated only $125,000 in annual revenue through 2022 and depends on a single lead candidate that has not received regulatory approval.
• BLA and regulatory timing risk — The planned Q4 2026 BLA submission for aglatimagene depends on completion of CMC, process validation and module preparation activities that may not be completed or accepted on schedule.
• Cash burn and financing need — Operating cash flow was -$38.3M in 2025 and the company had $201.6M of cash at June 30, 2026, which management expects to fund operations only into Q1 2028.
• Clinical trial risk in additional indications — The AURORA phase 3 trial in NSCLC and the planned linoserpaturev glioblastoma trial are early-stage efforts, and prostate cancer phase 3 results do not guarantee success in other tumor types.

Outlook

Management plans to submit a BLA for aglatimagene in localized, intermediate- to high-risk prostate cancer in Q4 2026 and is preparing for a potential U.S. commercial launch in 2027, if approved. The company states its $201.6 million cash balance at June 30, 2026 is expected to fund its current operating plan into Q1 2028, including commercial launch activities. Enrollment is open in the AURORA phase 3 trial in stage IV non-squamous NSCLC, and development planning continues for linoserpaturev in recurrent glioblastoma.